Payment overview · 2025
General Payments
$432.79
24 reported records · 10 companies
Healthcare provider profile · identity verified
Kenneth Chad Lambert, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · BETHANY, MO · NPI 1063704161
Verified facts
What the public records show
CMS Open Payments records show Kenneth Chad Lambert, D.O. received $432.79 in general payments during 2025 across 24 reported records.
Kerecis Limited accounted for 27.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Kerecis Limited | Unresolved — no canonical attribution shown | $118.85 | 27.5% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $98.11 | 22.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.89 | 11.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.47 | 8.4% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $34.50 | 8.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.77 | 7.1% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.27 | 4.2% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.88 | 3.9% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $14.96 | 3.5% | 1 | 2025 |
| MIMEDX Group, Inc. | Unresolved — no canonical attribution shown | $14.09 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $432.79 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerecis GraftGuide Normalized: kerecis graftguide |
Device | Kerecis Limited | $118.85 | 6 | 2025 |
Source payment records
|
|||||
| Kerecis SurgiClose Normalized: kerecis surgiclose |
Device | Kerecis Limited | $118.85 | 6 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $98.11 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $35.78 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $34.50 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 56 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
91 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
61 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
20 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 595 | 163 |
| Levothyroxine Sodium | Levothyroxine Sodium | 575 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 506 | 121 |
| Atorvastatin Calcium | Atorvastatin Calcium | 505 | 136 |
| Gabapentin | Gabapentin | 492 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 367 | 99 |
| Potassium Chloride | Potassium Chloride | 304 | 96 |
| Lisinopril | Lisinopril | 278 | 83 |
| Tramadol Hcl | Tramadol Hcl | 275 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 268 | 67 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 103 |
| Tamsulosin Hcl | Tamsulosin Hcl | 263 | 83 |
| Carvedilol | Carvedilol | 248 | 59 |
| Prednisone | Prednisone | 244 | 144 |
| Metoprolol Tartrate | Metoprolol Tartrate | 242 | 65 |
| Furosemide | Furosemide | 237 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 236 | 71 |
| Sertraline Hcl | Sertraline Hcl | 225 | 51 |
| Valsartan | Valsartan | 223 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 64 |
| Omeprazole | Omeprazole | 213 | 64 |
| Methylprednisolone | Methylprednisolone | 209 | 155 |
| Losartan Potassium | Losartan Potassium | 205 | 55 |
| Metformin Hcl | Metformin Hcl | 202 | 63 |
| Spironolactone | Spironolactone | 196 | 51 |
| Montelukast Sodium | Montelukast Sodium | 184 | 47 |
| Simvastatin | Simvastatin | 184 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 175 | 31 |
| Meloxicam | Meloxicam | 156 | 57 |
| Alprazolam | Alprazolam | 154 | 41 |
| Glimepiride | Glimepiride | 154 | 38 |
| Azithromycin | Azithromycin | 153 | 111 |
| Trazodone Hcl | Trazodone Hcl | 144 | 36 |
| Allopurinol | Allopurinol | 143 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 136 | 40 |
| Methocarbamol | Methocarbamol | 136 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 134 | 35 |
| Doxycycline Hyclate | Doxycycline Hyclate | 132 | 91 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 34 |
| Fluconazole | Fluconazole | 122 | 68 |
| Fluticasone Propionate | Fluticasone Propionate | 116 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 70 |
| Torsemide | Torsemide | 110 | 27 |
| Finasteride | Finasteride | 99 | 24 |
| Celecoxib | Celecoxib | 94 | 25 |
| Famotidine | Famotidine | 92 | 28 |
| Mounjaro | Tirzepatide | 91 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 90 | 28 |
| Warfarin Sodium | Warfarin Sodium | 88 | 20 |
| Jardiance | Empagliflozin | 83 | 23 |
| Topiramate | Topiramate | 83 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 29 |
| Donepezil Hcl | Donepezil Hcl | 82 | 15 |
| Eliquis | Apixaban | 81 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 77 | 59 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 40 |
| Memantine Hcl | Memantine Hcl | 73 | 15 |
| Nifedipine Er | Nifedipine | 73 | 24 |
| Aripiprazole | Aripiprazole | 72 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 72 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 26 |
| Xarelto | Rivaroxaban | 69 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 67 | 16 |
| Fenofibrate | Fenofibrate | 67 | 20 |
| Ezetimibe | Ezetimibe | 66 | 15 |
| Symbicort | Budesonide/Formoterol Fumarate | 65 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 63 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 62 | 19 |
| Nystatin | Nystatin | 62 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 14 |
| Trulicity | Dulaglutide | 61 | 14 |
| Pregabalin | Pregabalin | 59 | 20 |
| Ozempic | Semaglutide | 56 | 16 |
| Scopolamine | Scopolamine | 54 | 14 |
| Cephalexin | Cephalexin | 53 | 47 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 52 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 52 | 12 |
| Bupropion Xl | Bupropion Hcl | 50 | 15 |
| Terazosin Hcl | Terazosin Hcl | 50 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 12 |
| Lorazepam | Lorazepam | 49 | 15 |
| Clonidine Hcl | Clonidine Hcl | 48 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 48 | 13 |
| Glipizide Er | Glipizide | 47 | 16 |
| Ondansetron Odt | Ondansetron | 47 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 45 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | 11 |
| Levofloxacin | Levofloxacin | 42 | 29 |
| Ventolin Hfa | Albuterol Sulfate | 42 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 41 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 12 |
| Atenolol | Atenolol | 39 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 39 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 35 |
| Glipizide | Glipizide | 36 | 11 |
| Sucralfate | Sucralfate | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Synthroid | Levothyroxine Sodium | 34 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | 12 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 33 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 33 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Amoxicillin | Amoxicillin | 30 | 27 |
| Diazepam | Diazepam | 30 | 19 |
| Digoxin | Digoxin | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Irbesartan | Irbesartan | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 18 |
| Propranolol Hcl | Propranolol Hcl | 27 | 11 |
| Sotalol | Sotalol Hcl | 27 | suppressed |
| Trimethoprim | Trimethoprim | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Metronidazole | Metronidazole | 24 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 19 |
| Bupropion Hcl | Bupropion Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Anastrozole | Anastrozole | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 11 |
| Fluorouracil | Fluorouracil | 17 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 17 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 17 | 12 |
| Temazepam | Temazepam | 17 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 14 | suppressed |
| Lactulose | Lactulose | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 11 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $432.79 · 24 records | Kerecis Limited | ELIQUIS, EVENITY, JARDIANCE, JOURNAVX, Kerecis GraftGuide, Kerecis SurgiClose, LEQVIO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, VRAYLAR, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error